Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Absence of p16 gene (CDKN2) deletions in microdissected primary breast carcinoma specimens.

Annals of surgical oncology - 1 Jan 2000

Calvano J E, Rush E B, Tan L K, Rosen P P, Borgen P I, Van Zee K J

Abstract excerpt

BACKGROUND: The p16 gene (CDKN2), a tumor suppressor gene located on chromosome 9p21, has been demonstrated to be mutated or deleted with high frequency in a variety of tumor cell lines, including breast. While previous studies have not demonstrated CDKN2 mutations in primary breast carcinomas, it is possible that gene deletion in neoplastic DNA was marked by the presence of contaminating normal stromal DNA in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Carrier Proteins
Share to DNA, Neoplasm

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Gene Deletion

Share to Genes, Tumor Suppressor

Share to Mutation

Share to Polymerase Chain Reaction

Share to Polymorphism, Single-Stranded Conformational

Source

Identifiers

PMID: 9259969
DOI: 10.1007/BF02305555

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Absence of p16 gene (CDKN2) deletions in microdissected primary breast carcinoma specimens.PMID 9259969Read ↗

Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells.Semantic proximity Read ↗

p16 (CDKN2/cyclin-dependent kinase-4 inhibitor/multiple tumor suppressor-1) gene is not altered in uterine cervical carcinomas or cell lines.Semantic proximity Read ↗

Infrequent CDKN2 (MTS1/p16) gene alterations in human primary breast cancer.Semantic proximity Read ↗

Genomic DNA and messenger RNA expression alterations of the CDKN2B and CDKN2 genes in esophageal squamous carcinoma cell lines.Semantic proximity Read ↗

Mutation rate of the CDKN2 gene in malignant gliomas.Semantic proximity Read ↗

Low frequency of CDKN2 mutation in endometrial carcinomas.Semantic proximity Read ↗

Intragenic mutations of CDKN2B and CDKN2A in primary human esophageal cancersSemantic proximity Read ↗

Mutational alteration of the p16CDKN2a tumor suppressor gene is infrequent in Ewing's sarcoma.Semantic proximity Read ↗

No CDKN2 mutations in neuroblastomas.Semantic proximity Read ↗

Mutations of the p16 gene product are rare in prostate cancer.Semantic proximity Read ↗

Analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, andCDKN2C) in childhood rhabdomyosarcomaSemantic proximity Read ↗

Deletion or lack of expression of CDKN2 (CDK4I/MTS1/INK4A) and MTS2 (INK4B) in acute lymphoblastic leukemia cell lines reflects the phenotype of the uncultured primary leukemia cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.